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A B S T R A C T
Background: Transcatheter aortic valve implantation (TAVI) has become the treatment of choice for the
symptomatic patients with aortic stenosis (AS) and high surgical risk. Pulmonary hypertension (PHTN)
has been shown to be associated with worse early and late outcomes after aortic valve surgery. Data
regarding the effect of TAVI on PHTN are limited.
Methods and results: We evaluated the characteristics and outcome of the patients with various degrees
of systolic PHTN referred for TAVI. PHTN was deﬁned as systolic pulmonary arterial pressure (SPAP)
50 mmHg as assessed by echocardiography. The patients with SPAP decrease after TAVI to below
50 mmHg were compared to the patients with persistent PHTN following TAVI. Of the 122 patients
included in the present study, 49 (40%) patients had elevated SPAP prior to TAVI. This group of patients
presented with smaller aortic valve areas, greater degrees of mitral or tricuspid regurgitation, lower left
ventricular ejection fraction, and more prevalent chronic obstructive pulmonary disease (COPD) (all
p < 0.05). Following TAVI, 57% of the patients with prior PHTN experienced a reduction in SPAP to below
50 mmHg. Multivariable analysis identiﬁed COPD to be the most powerful predictor for PHTN presence
post-TAVI (hazard ratio 3.9, 95% conﬁdence interval 1.5–9.9, p = 0.005). Post-TAVI PHTN (SPAP
50 mmHg) was associated with a 3.4-fold, independent, 2-year mortality risk (p = 0.04).
Conclusions: Our data suggest that TAVI is associated with a signiﬁcant reduction in pulmonary pressure
in more than half of the patients with preprocedural PHTN. COPD identiﬁes the patients with persistent
PHTN after TAVI. Post-TAVI PHTN is associated with markedly worse outcome.
 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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Transcatheter aortic valve implantation (TAVI) has emerged as
an excellent alternative to surgical aortic valve replacement (AVR)
for the symptomatic patients with high-risk or inoperable aortic
stenosis (AS) [1–4]. Pulmonary hypertension (PHTN) is the end
result of a variety of diverse pathologic cardiac processes [5]. It has
been shown to be associated with worse early and late outcomes
after aortic valve surgery [6,7], and is an important determinant of
surgical risk in the contemporary risk scores. In the patients with
left-sided cardiac disease, PHTN is common and associated with* Corresponding author at: The Heart Center, Chaim Sheba Medical Center,
Tel Hashomer, 55261 Israel. Tel.: +972 52 6667581; fax: +972 3 5303190.
E-mail address: amit.segev@sheba.health.gov.il (A. Segev).
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http://dx.doi.org/10.1016/j.jjcc.2014.06.008
0914-5087/ 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardioloincreased morbidity and mortality. The chronic elevation in
pulmonary artery pressure often leads to right ventricular pressure
overload and subsequent right ventricular failure. In the patients
with severe AS, PHTN is a common ﬁnding reﬂecting long-standing
stenosis, unrelated to systolic ventricular function. Whether PHTN
is a marker of irreversible myocardial damage is not known and
data regarding the effect of TAVI on PHTN are limited. We aimed
to identify predictors of persistent PHTN following TAVI, and to
evaluate the long-term signiﬁcance of PHTN presence after TAVI.
Methods
Study population and deﬁnitions
The study population comprised of 122 patients who under-
went TAVI at Sheba Medical Center between 2009 and 2011 andgy.
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baseline. PHTN was deﬁned as systolic pulmonary arterial pressure
(SPAP) 50 mmHg as assessed by echocardiography. Kidney
dysfunction was deﬁned as admission estimated glomerular
ﬁltration rate (eGFR) <60 ml/min/1.73 m2. The diagnosis of
chronic obstructive pulmonary disease (COPD) was obtained from
medical records and considered signiﬁcant if severity was greater
than mild according to spirometry results following the American
Thoracic Society (ATS) criteria [8].
The patients were divided into two groups according to the
baseline SPAP (50 mmHg and <50 mmHg). Follow-up echocar-
diographic examination was performed at an average of 6.5
months following the procedure. Clinical follow-up was performed
at 2 years. Mortality data were obtained from the Israeli national
population registry.
Echocardiographic assessment
Doppler tracings and two-dimensional images were obtained
from parasternal long- and short-axis, apical four-chamber, and
subcostal four-chamber views. TR was identiﬁed by color ﬂow
Doppler techniques. Continuous-wave Doppler measured maxi-
mum jet velocity. Right ventricular systolic pressure was estimated
based on the modiﬁed Bernoulli equation and was considered
equal to the SPAP in the absence of right ventricular outﬂow
obstruction. SPAP was calculated by adding transtricuspid
pressure gradient to mean right atrial pressure estimated from
inferior vena cava diameter and motion during respiration as
follows: if the caliber of inferior vena cava (IVC) was normal
(1.5–2.5 cm), mean right atrial pressure was estimated to be
5 mmHg if there was complete collapse of the IVC during
inspiration, whereas mean right atrial pressure was estimated to
be 10 mmHg if IVC collapse was <50%. If IVC was dilated, mean
right atrial pressure was estimated to be 15 mmHg, and if the IVC
collapsed by <50% with inspiration, atrial pressure was estimated
to be 20 mmHg. Left ventricular end-diastolic and end-systolic
volumes were measured by biplane Simpson’s method and the left
ventricular ejection fraction (LVEF) was estimated. Aortic valve
morphology was evaluated at the parasternal short-axis view. Left
ventricular outﬂow tract diameter and aortic annulus, sinus and
sino-tubular junction diameters were measured at the parasternal
long-axis view. Continuous-wave Doppler recordings through the
aortic valve were obtained and peak and mean transaortic pressure
gradients were calculated. Aortic valve area was calculated by
continuity equation.
Aortic regurgitation (AR) was evaluated by color Doppler
echocardiography after optimizing gain and Nyquist limit.
Speciﬁcally, routine measurements included semi-quantitative
parameters of AR severity such as jet width, vena contracta, and
assessment of pressure half-time and holodiastolic ﬂow reversal in
the descending aorta.
TAVI procedure
All the patients with severe AS treated by TAVI were assessed
by a dedicated ‘‘Heart Team’’ and were considered inoperable or
high-risk for conventional surgery. The decision between the
two available valves was at the discretion of the heart team and
was based on annular size, diameter of femoral arteries, degree
of calciﬁcation, and dilation of the ascending aorta. TAVI was
performed using general or local anesthesia. Temporary
pacemaker was inserted in all the patients and balloon
valvuloplasty was performed under rapid pacing. Valve implan-
tation was performed subsequently, while postdilation was
performed if necessary, in cases of signiﬁcant angiographic,
echocardiographic, or hemodynamically signiﬁcant AR. Vascularaccess site closure was obtained by Prostar1 (Abbott, Abbott
Park, IL, USA). Postprocedure, all the patients were hospitalized
in the intensive cardiac care unit for 48–72 h and were
monitored for potential complications, including conduction
disturbances.
Statistical analysis
Characteristics of study participants were compared using x2
test for categorical variables and also by Student’s t-test or
Wilcoxon rank tests, as appropriate for continuous variables. The
Kruskal–Wallis test was used for comparison of non-normally
distributed continuous variables. Study design is a landmark
analysis following the post-TAVI echocardiography.
Multivariate logistic regression modeling was used to identify
independent predictors associated with PHTN presence following
TAVI. The following covariates were introduced into the model
using the best subset method: age, severity grades (0 to +3) of MR,
AR, and TR, LVEF, diagnosis of coronary artery disease (CAD), aortic
valve area (in cm2), and diagnosis of COPD (deﬁned as disease
severity > mild).
We performed a landmark analysis including only those
patients who underwent at least one follow-up echocardiographic
study, following hospital discharge. Kaplan–Meier survival analy-
sis was used to construct the cumulative 2-year survival
probability curves by PHTN presence on follow-up echocardiogra-
phy, and the log-rank test was used to declare signiﬁcance.
Mortality outcome was explored for each group according to the
Kaplan–Meier method and graphically presented. Cox proportional
hazards method was used to evaluate the independent effects of
post-TAVI PHTN on the 2-year all-cause mortality outcome.
The following covariates were introduced into the model: age,
presence of CAD, COPD, New York Heart Association functional
class, LVEF, post-TAVI SPAP 50 mmHg, and presence of renal
dysfunction. A separate regression model was constructed as
above, with the exception that baseline pre-TAVI SPAP 50 mmHg
was introduced, instead of post-TAVI PHTN values. Consistent
results were obtained when SPAP results were introduced as
continuous values in all the models.
A two-sided value of p < 0.05 was used for declaring statistical
signiﬁcance. All data analyses were performed using SPSS
statistical software (IBM, Chicago, IL, USA), version 20.
Results
The study population consisted of 122 patients divided into
two groups according to the baseline SPAP. SPAP was successfully
assessed by a TR signal on echocardiography in all the patients.
Seventy-three patients (60%) had baseline SPAP <50 mmHg and
49 patients (40%) had baseline SPAP 50 mmHg. Fig. 1 shows the
ﬂow chart of the patients in our study. Within 3 months
postprocedure, 13 patients (17%) died in the SPAP <50 group,
and 5 (10%) in the SPAP 50 group. These patients had no available
echocardiography data at follow-up and were excluded from the
ﬁnal analysis. As shown in Table 1, baseline characteristics were
similar between the groups, except that the SPAP 50 group had
signiﬁcantly higher EuroSCORE (33 vs. 26, p = 0.01) and higher
percentage of COPD (49% vs. 27%, p = 0.02). A lower percentage of
CAD was also observed in the SPAP 50 group (44% vs. 64%,
p = 0.03). Baseline echocardiography (Table 2) was performed
before TAVI showed that the SPAP 50 group had signiﬁcantly
lower LVEF (49% vs. 54%, p = 0.03), smaller aortic valve area
(0.63 cm2 vs. 0.72 cm2, p = 0.003), more concomitant valvular
abnormalities, such as moderate to severe MR (44% vs. 20%,
p = 0.03) and TR (42% vs. 8%, p < 0.001). Procedural details are
summarized in Table 3.
Fig. 1. Patients’ ﬂow chart in our study. TAVI, transcatheter aortic valve
implantation; SPAP, systolic pulmonary arterial pressure.
Table 3
Procedural characteristics.
SPAP <50 mmHg SPAP 50 mmHg p value
N = 73 N = 49
Valve type
Edwards-Sapien, N (%) 20 (16.4) 4 (3.3) 0.009
CoreValve, N (%) 53 (43.4) 45 (36.9)
General anesthesia, N (%) 40 (55) 29 (59) 0.69
Residual aortic
regurgitation >1 (%)
8 (6.5) 3 (2.5) 0.1
Major vascular
complication, N (%)
11 (15) 5 (10) 0.42
Permanent pacemaker, N (%) 24 (33) 18 (37) 0.63
Hospital stay (days),
mean  SD
7  4 8  5 0.2
SPAP, systolic pulmonary arterial pressure.
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deaths, ﬁnal analysis and follow-up were available in 44 patients
with baseline SPAP 50 mmHg, and in 60 patients with baseline
SPAP <50 mmHg. Fig. 2A shows that overall, TAVI resulted in
signiﬁcant reduction of PHTN from 48.9 mmHg to 45.1 mmHg
(p = 0.004). In the patients with baseline SPAP 50, mean PHTN
signiﬁcantly decreased from 64.6 mmHg to 52.5 mmHg (p < 0.01)
(Fig. 2B). Interestingly, 17% of the patients with baseline SPAP <50
had SPAP 50 mmHg after the procedure.Table 1
Baseline clinical characteristics.
SPAP <50 mmHg SPAP 50 mmHg p value
N = 73 N = 49
Age (years), mean  SD 81  6.4 81  8
Male (%) 57 43 0.5
Baseline creatinine (mg%),
mean  SD
1.2  0.4 1.5  1.3 0.2
EuroSCORE (%), mean  SD 26  15 33  13 0.01
NYHA functional class
III (%) 86 78 0.3
IV (%) 14 20
Coronary artery disease (%) 64 44 0.03
Chronic lung disease (%) 27 49 0.02
Diabetes mellitus (%) 31 32 0.8
Peripheral vascular
disease (%)
13 12 0.8
SPAP, systolic pulmonary arterial pressure; NYHA, New York Heart Association.
Table 2
Echocardiographic characteristics.
SPAP <50 mmHg SPAP 50 mmHg p value
N = 73 N = 49
LVEF (%), mean  SD 54  12 49  14 0.03
Aortic valve area (cm2),
mean  SD
0.72  0.17 0.63  0.13 0.003
Maximal AV gradient
(mmHg), mean  SD
74  25 73  24 0.7
Mean AV gradient
(mmHg), mean  SD
48  20 45  16 0.4
SPAP (mmHg), mean  SD 37  6 64  10 <0.001
Moderate–severe MR (%) 20.9 44.8 0.03
Moderate–severe TR (%) 8.3 2.8 <0.001
SPAP, systolic pulmonary artery pressure; LVEF, left ventricular ejection
fraction; AV, aortic valve; MR, mitral regurgitation; TR, tricuspid regurgitation.Independent predictors of pulmonary hypertension after TAVI
Following TAVI, 31 patients had SPAP 50 mmHg. Results of the
regression model are summarized in Table 4. COPD was found to be
independently associated with a 3.4-fold greater likelihood of
post-TAVI PHTN, and the sole signiﬁcant predictor. Important
clinical and echocardiographic characteristics, including age, aortic
valve area, grade of MR, AR, or TR, LVEF and diagnosis of coronary
heart disease, were not associated with PHTN after TAVI.
Moreover, one-way ANOVA analysis demonstrated nonsignif-
icant differences (p value = 0.58) among mean SPAP values and
the prespeciﬁed degrees of AR (graded from 0 to +3) following the
TAVI procedure. Consistently, introduction of the AR grade in the
logistic regression model demonstrated a nonsigniﬁcant associ-Fig. 2. Mean systolic pulmonary arterial pressure (SPAP) before and after
transcatheter aortic valve implantation.
Table 4
Independent predictors for post-transcatheter aortic valve implantation for
presence of pulmonary hypertension.
OR 95% CI p value
Lower Upper
COPD 3.40 1.25 9.23 0.02
NYHA FC III–IV 1.38 0.40 4.76 0.62
Age (per 1-year increment) 0.97 0.90 1.04 0.35
LVEF 0.99 0.95 1.03 0.60
Prior renal dysfunction 2.19 0.84 5.74 0.11
AVA 0.13 0.01 2.89 0.20
TR grade 1.19 0.47 3.05 0.76
MR grade 1.21 0.80 1.84 0.37
OR, odds ratio; CI, conﬁdence interval; COPD, chronic obstructive pulmonary
disease; NYHA FC, New York Heart Association functional class; LVEF, left
ventricular ejection fraction; AVA, aortic valve area; TR, tricuspid regurgitation;
MR, mitral regurgitation.
Fig. 4. 2-Year mortality rate by pulmonary hypertension before and after
transcatheter aortic valve implantation.
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of post-TAVI PHTN.
Mortality outcome
Kaplan–Meier 2-year survival analysis in the patients under-
going TAVI by the presence of SPAP 50 mmHg on follow-up
echocardiography is shown in Fig. 3. The patients with PHTN after
TAVI had a signiﬁcantly higher mortality probability at 2 years,
compared to the patients with post-TAVI SPAP <50 mmHg (25.8%
vs. 9.5%, log-rank p = 0.013). Fig. 4 shows 2-year mortality rates
according to pre- and post-procedural PHTN. Consistent with the
univariate data, multivariate analysis demonstrated that the
patients with post-TAVI PHTN have marked independent 3.4-fold
2-year mortality risk. Results of the multivariate analysis are
summarized in Table 5. Renal dysfunction at baseline was the only
additional signiﬁcant mortality predictor (hazard ratio 1.90, 95%
conﬁdence interval 1.34–2.70, p < 0.001). Baseline pre-TAVI SPAP
50 mmHg was not signiﬁcantly associated with a 2-year survival
(p = 0.07), nor was the presence of COPD (p = 0.09).Fig. 3. Kaplan–Meier curves of cumulative (Cum) probability for 2-year survivalDiscussion
The main ﬁnding of the present study is that among elderly and
high-risk patients with severe AS undergoing TAVI, the procedure
leads to SPAP reduction in more than half of the patients with
baseline PHTN. The patients with COPD are at increased risk of
suffering from PHTN presence after TAVI. Persistent PHTN is
associated with a worse prognosis and is a signiﬁcant independent
predictor of 2-year mortality, probably reﬂecting irreversible
myocardial damage or irreversible pulmonary vascular resistance.
Pulmonary hypertension is common in the patients with severe
AS [9–12]. Previous studies showed that in the patients undergoing
surgical aortic valve replacement for AS, baseline PHTN and its
severity are associated with mortality, serious complications, and
worse late survival [13–16]. Data regarding the effect of TAVI on
PHTN are limited. A single center analysis of the patients was
included in the PARTNER trial [17], which included 69 patients
undergoing TAVI and showed that the patients with severe AS and
increased SPAP experience increased mortality rates. A similar
association between PHTN and increased mortality was observed
in the Canadian experience [18] which included 345 TAVI
procedures. Another study [19] examined the patients undergoing
TAVI with concomitant moderate or severe MR at baseline. At by postprocedure systolic pulmonary arterial pressure (SPAP) 50 mmHg.
Table 5
Multivariate Cox regression model for 2-year mortality outcome.
HR 95% CI p value
Lower Upper
Post-TAVI SPAP 50 mmHg 3.52 1.08 11.44 0.04
NYHA FC III–IV 3.30 0.88 12.44 0.08
CAD 2.94 0.83 10.46 0.10
Prior renal dysfunction 1.90 1.34 2.70 <0.001
Age 0.96 0.89 1.04 0.33
LVEF 1.01 0.96 1.05 0.83
HR, hazard ratio; CI, conﬁdence interval; TAVI, transcatheter aortic valve
implantation; SPAP, systolic pulmonary artery pressure; NYHA FC, New York
Heart Association functional class; LVEF, left ventricular ejection fraction; CAD,
coronary artery disease.
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improvement was more likely in the patients with high transaortic
gradients, functional MR, and absence of PHTN. Furthermore, left
ventricular diastolic dysfunction with impaired relaxation is
observed in the majority of the patients with advanced PHTN
worsening their prognosis [20–23].
In our single-center small study we found that in the patients
with severe AS undergoing TAVI, concomitant PHTN is associated
with worse baseline characteristics, higher EuroSCORE, higher
rates of COPD, lower LVEF, smaller aortic valve area, and more
concomitant signiﬁcant mitral or tricuspid disease. After TAVI,
PHTN was decreased in slightly more than half of the patients
(from 64.6 mmHg to 52.5 mmHg, p < 0.01). Interestingly, 17% of
the patients with baseline SPAP <50 mmHg had increased levels
after the procedure, which may reﬂect residual AR. After
multivariable analysis, we were able to identify COPD as the only
independent predictor of persistent PHTN after TAVI. The group
with persistent PHTN after TAVI had signiﬁcantly higher 2-year
mortality rate; persistent PHTN and preprocedural renal dysfunc-
tion were identiﬁed as the only signiﬁcant predictors for the 2-year
mortality outcome. Data from a European registry of 942 patients
undergoing TAVI also found severe chronic kidney disease,
especially those under chronic dialysis to be an independent
predictor of worse 30-day and 1-year outcome [24]. Of interest, the
patients with persistent PHTN after TAVI have increased early
mortality (3 months) as compared to the patients without PHTN.
This may reﬂect the impact of the procedure itself in a sicker
population with other comorbidities, especially COPD, or irrevers-
ible left ventricular dysfunction (systolic and diastolic).
The next task in the assessment of high-risk or inoperable
patients with severe AS for the potential beneﬁt from TAVI is to
identify the patients who are ‘‘beyond’’ TAVI. The PARTNER study
of cohort B patients showed that the patients with the highest
EuroSCORE do not beneﬁt from TAVI when compared to medical
therapy [3]. This group should be identiﬁed and turned down for
TAVI. The group may include the patients with signiﬁcant chronic
lung disease with PHTN and irreversible diastolic dysfunction that
is manifested by PHTN. The role of cardiac magnetic resonance for
the assessment of severe myocardial ﬁbrosis should be further
assessed [25]. Indeed, in a pathological study of the patients
undergoing surgical AVR for severe AS, patients with biopsy-
proven myocardial ﬁbrosis did not beneﬁt from surgery [26].
Limitations of the present study include the fact that the data
were taken from a single center registry with a relatively small
group of the patients. Another important limitation is the fact that
the assessment of PHTN was based only on the echocardiography
examination and not on cardiac catheterization. Evaluation of SPAP
by echocardiography has a number of known limitations relevant
to this study, such as systemic blood pressure during the test;
nevertheless it is the most common noninvasive method for theevaluation of PHTN. Moreover, the patients with early mortality
were excluded.
In conclusion, in high-risk or inoperable patients with severe AS
and PHTN, TAVI is associated with a signiﬁcant PHTN reduction.
The patients with COPD have an increased risk to suffer from
persistent PHTN after TAVI. The presence of PHTN after TAVI
identiﬁes the patients with a worse prognosis and is a signiﬁcant
independent predictor of a 2-year mortality.
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